Randomized Trial of Clarithromycin for Mediterranean Spotted Fever.

Area of Science:

• Infectious Diseases
• Pharmacology
• Clinical Medicine

Background:

• Mediterranean spotted fever (MSF) is typically treated with tetracyclines or chloramphenicol.
• Chloramphenicol's bone marrow toxicity favors tetracyclines, but alternatives are needed for specific patient groups.
• Alternative antibiotics are crucial for patients with tetracycline allergies, pregnant women, and young children.

Purpose of the Study:

• To evaluate clarithromycin as an alternative antibiotic for Mediterranean spotted fever.
• To compare the efficacy and safety of clarithromycin against doxycycline or josamycin in MSF treatment.
• To assess treatment outcomes in patients with MSF receiving clarithromycin versus other standard therapies.

Main Methods:

• A randomized clinical trial was conducted involving 40 patients diagnosed with Mediterranean spotted fever.
• Patients were divided into two groups: one receiving clarithromycin and the other receiving doxycycline or josamycin.
• Outcomes measured included time to fever resolution, symptom disappearance, and adverse reactions.

Main Results:

• No significant difference was observed in the time to fever disappearance between the clarithromycin group (2.67 ± 1.55 days) and the doxycycline/josamycin group (2.22 ± 1.35 days).
• Symptom resolution times were also comparable, with 4.70 ± 2.25 days for clarithromycin versus 4.75 ± 3.08 days for doxycycline/josamycin.
• No adverse reactions or relapses were reported in either treatment group, indicating good tolerability.

Conclusions:

• Clarithromycin demonstrates comparable efficacy to doxycycline or josamycin in treating Mediterranean spotted fever.
• It serves as a safe and effective alternative antibiotic option for MSF patients.
• The study supports the use of clarithromycin for patients who cannot tolerate or are contraindicated for tetracyclines.